Effects and Safety of an Oral Adsorbent on Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis

Overview

Journal J Clin Med

Specialty General Medicine

Date 2019 Oct 20

PMID 31627462

Citations 13

Authors

Ying-Chun Chen

Mei-Yi Wu

Ping-Jen Hu

Tzu-Ting Chen

Wan-Chen Shen

Wei-Chiao Chang

Mai-Szu Wu

Affiliations

Soon will be listed here.

Abstract

Background: AST-120 (Kremezin), which is an oral spherical carbon adsorbent, has been reported to have the potential for retarding disease progression in patients with chronic kidney disease. We aimed to evaluate its efficacy and safety in this study.

Methods: We systematically searched for randomized controlled trials published in PubMed, Embase, and Cochrane databases. The primary outcomes were the renal outcome and all-cause mortality, and the change in serum indoxyl sulfate (IS) levels. The safety outcome was also evaluated in terms of reported major adverse events. A random-effects model was used when heterogeneity was expected.

Results: Eight studies providing data for 3349 patients were included in the meta-analysis. The risk ratio of renal outcome and all-cause mortality were 0.97 (95% CI: 0.88-1.07; 6 trials) and 0.94 (0.73-1.20; 5 trials), respectively. Furthermore, the weighted mean change in IS levels from baseline to the end of the study was -0.28 mg/dL (95% CI: -0.46 to -0.11; 4 trials).

Conclusions: This study provides evidence that AST-120 can effectively lower IS levels but still controversial in terms of slowing disease progression and all-cause mortality. Except for dermatological events, the incidence of adverse events did not differ significantly between the AST-120 and placebo groups.

Citing Articles

Advances in kidney disease: pathogenesis and therapeutic targets.

Boima V, Agyekum A, Ganatra K, Agyekum F, Kwakyi E, Inusah J Front Med (Lausanne). 2025; 12:1526090.

PMID: 40027896 PMC: 11868101. DOI: 10.3389/fmed.2025.1526090.

Uremic toxins mediate kidney diseases: the role of aryl hydrocarbon receptor.

Xie H, Yang N, Yu C, Lu L Cell Mol Biol Lett. 2024; 29(1):38.

PMID: 38491448 PMC: 10943832. DOI: 10.1186/s11658-024-00550-4.

Tissue Factor, Thrombosis, and Chronic Kidney Disease.

Oe Y, Takahashi N Biomedicines. 2022; 10(11).

PMID: 36359257 PMC: 9687479. DOI: 10.3390/biomedicines10112737.

Microbial-Derived Tryptophan Catabolites, Kidney Disease and Gut Inflammation.

Madella A, van Bergenhenegouwen J, Garssen J, Masereeuw R, Overbeek S Toxins (Basel). 2022; 14(9).

PMID: 36136583 PMC: 9505404. DOI: 10.3390/toxins14090645.

The Dual Roles of Protein-Bound Solutes as Toxins and Signaling Molecules in Uremia.

Masereeuw R Toxins (Basel). 2022; 14(6).

PMID: 35737063 PMC: 9230939. DOI: 10.3390/toxins14060402.

References

Liyanage T, Ninomiya T, Jha V, Neal B, Patrice H, Okpechi I . Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015; 385(9981):1975-82. DOI: 10.1016/S0140-6736(14)61601-9. View

Schulman G, Berl T, Beck G, Remuzzi G, Ritz E, Shimizu M . Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120. Clin Exp Nephrol. 2017; 22(2):299-308. PMC: 5838144. DOI: 10.1007/s10157-017-1447-0. View

Yorioka N, Kiribayashi K, Naito T, Ogata S, Yokoyama Y, Kyuden Y . An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease. J Nephrol. 2008; 21(2):213-20. View

Niwa T . Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr. 2010; 20(5 Suppl):S2-6. DOI: 10.1053/j.jrn.2010.05.002. View

. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012; 60(5):850-86. DOI: 10.1053/j.ajkd.2012.07.005. View

Matsushita K, van der Velde M, Astor B, Woodward M, Levey A, de Jong P . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073-81. PMC: 3993088. DOI: 10.1016/S0140-6736(10)60674-5. View

Vanholder R, Schepers E, Pletinck A, Nagler E, Glorieux G . The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 2014; 25(9):1897-907. PMC: 4147984. DOI: 10.1681/ASN.2013101062. View

Chen W, Chen Y, Hsieh M, Huang S, Kao Y, Chen Y . The uremic toxin indoxyl sulfate increases pulmonary vein and atrial arrhythmogenesis. J Cardiovasc Electrophysiol. 2014; 26(2):203-10. DOI: 10.1111/jce.12554. View

Tang W, Wang C, Chung F, Huang L, Yu T, Hung W . Uremic retention solute indoxyl sulfate level is associated with prolonged QTc interval in early CKD patients. PLoS One. 2015; 10(3):e0119545. PMC: 4403985. DOI: 10.1371/journal.pone.0119545. View

10.

Owada A, Nakao M, Koike J, Ujiie K, Tomita K, Shiigai T . Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int Suppl. 1998; 63:S188-90. View

11.

Hatakeyama S, Yamamoto H, Okamoto A, Imanishi K, Tokui N, Okamoto T . Effect of an Oral Adsorbent, AST-120, on Dialysis Initiation and Survival in Patients with Chronic Kidney Disease. Int J Nephrol. 2012; 2012:376128. PMC: 3263620. DOI: 10.1155/2012/376128. View

12.

Cha R, Kang S, Park C, Cha D, Na K, Kim S . A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal Dysfunction. Clin J Am Soc Nephrol. 2016; 11(4):559-67. PMC: 4822676. DOI: 10.2215/CJN.12011214. View

13.

Okada K, Matsumoto K, Takahashi S . Uremic toxins adsorbed by AST-120 promote tubular hypertrophy and interstitial fibrosis in nephrectomized rats. Kidney Blood Press Res. 2004; 28(1):8-13. DOI: 10.1159/000080935. View

14.

. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43(5 Suppl 1):S1-290. View

15.

Asai M, Kumakura S, Kikuchi M . Review of the efficacy of AST-120 (KREMEZIN) on renal function in chronic kidney disease patients. Ren Fail. 2019; 41(1):47-56. PMC: 6374968. View

16.

Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S . Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009; 54(3):459-67. DOI: 10.1053/j.ajkd.2009.05.011. View

17.

Hung S, Kuo K, Huang H, Lin C, Tsai T, Wang C . Indoxyl sulfate suppresses endothelial progenitor cell-mediated neovascularization. Kidney Int. 2016; 89(3):574-85. DOI: 10.1016/j.kint.2015.11.020. View

18.

Gelasco A, Raymond J . Indoxyl sulfate induces complex redox alterations in mesangial cells. Am J Physiol Renal Physiol. 2006; 290(6):F1551-8. DOI: 10.1152/ajprenal.00281.2004. View

19.

Nakagawa N, Hasebe N, Sumitomo K, Fujino T, Fukuzawa J, Hirayama T . An oral adsorbent, AST-120, suppresses oxidative stress in uremic rats. Am J Nephrol. 2006; 26(5):455-61. DOI: 10.1159/000096423. View

20.

Cha R, Kang S, Park C, Cha D, Na K, Kim S . Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: analysis of the Kremezin Study against renal disease progression in Korea. Kidney Res Clin Pract. 2017; 36(1):68-78. PMC: 5331977. DOI: 10.23876/j.krcp.2017.36.1.68. View